Given that VEN+AUR combination works independently of p53 status and that TP53 mutations are important prognostic parameters for BCP-ALL patients, it may be beneficial to include AUR in novel, VEN-containing drug combinations tested for the efficacy in R/R BCP-ALL patients with TP53 mutations. This evidence concerns the gene TP53 and acute lymphoblastic leukemia.